Clinical Trials
Below are current clinical trials.
349 studies in Children's Research Center (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Rochester, Minn.
The purpose of this study is to determine if a medical record prompt at the time of a medical consult will help to address lapses in routine immunizations, including the HPV vaccine.
-
Rochester, Minn.
The purpose of this study is to measure the blood level of vitamin D in normal weight adolescents following a 12-week supplementation with Vitamin D3 2000 IU/day.
-
Rochester, Minn.
The primary purpose of this study is to generate pediatric-specific reference ranges that take into account patient sex, age, corrected gestational age, ethnicity, etc., and laboratory variables for various coagulation studies.
-
The purpose of this study is to establish reference ranges for the Premier Hb210TM Resolution system in regard to hemoglobins A0, A2, and F for use in providing information for the comparative decision-making process in physiological assessment, medical diagnosis and therapeutic management of patients.
-
Rochester, Minn.
The study is being done to look for markers in the blood and/or stored kidney biopsy tissue, in patients with a history of childhood onset Membranous Nephropathy. By collecting health information and laboratory samples, our goal is to learn more about membranous nephropathy.
Due to discovery of additional antibodies and antigens (Thrombospondin Type-1 Domain 7A, Semaphorin 3B, Exotosin-1 & 2, Neural epidermal growth factor-like type 1, Protocadherin 7 PCDH7, Protocadherin FAT1, and serine protease HTRA1) in children with MN over the last decade, we would like to expand serological and hisotological testing of these antibodies and antigens in the existing and archived samples to ensure a comprehensive investigation of this disease in the current study.
-
Rochester, Minn.
Wiskott - Aldrich syndrome (WAS) is a rare serious medical condition that causes problems both with the immune system and with easy bruising and bleeding. The immune abnormalities cause patients with WAS to be very susceptible to infections. Depending on the specific type of primary immune deficiency diseases, there are effective treatments, including antibiotics, cellular therapy and gene therapy, but studies of large numbers of patients are needed to determine the full range of causes, natural history, or the best methods of treatment for long term success. This multicenter study combines retrospective, prospective and cross-sectional analyses of the transplant experiences for patients with WAS who have already received Hematopoietic cell transplant (HCT) since 1990, or who will undergo HCT during the study period. The retrospective and prospective portions of the study will address the impact of a number of pre and post-transplant factors on post-transplant disease correction and ultimate benefit from HCT. The cross-sectional portion of the study will assess the benefit of HCT 2 years post-HCT.
-
Rochester, Minn.
The primary objective of this study is to determine whether administration of FCX-007 in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Recessive Dystrophic Epidermolysis Bullosa (RDEB) and confirmed mutation of the type VII collagen gene (COL7A1) gene.
-
Scottsdale/Phoenix, Ariz.
The purpose of this extension study is to investigate the safety of using cannabidiol in children and young adults with Dravet or Lennox-Gastaut syndromes that are not well controlled.
-
Rochester, Minn.
The purpose of this study is to see how well lorvotuzumab mertansine works in treating younger patients with Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor (MPNST), or synovial sarcoma that has returned or that does not respond to treatment. Antibody-drug conjugates, such as lorvotuzumab mertansine, are created by attaching an antibody (protein used by the body's immune system to fight foreign or diseased cells) to an anti-cancer drug. The antibody is used to recognize tumor cells so the anti-cancer drug can kill them.
-
Rochester, Minn.
It is unclear if and how COVID19 can be passed from mother to child. Therefore, we aim to collect maternal and fetal samples from COVID19-infected pregnant women and compare them to pregnant women who have clinical indications for COVID 19 testing at the time of hospital admission but end up being COVID19- (control group). Pregnant women who are either COVID19+ or COVID19- with symptoms will be followed during this study. Our objective is to understand the prevalence of maternal fetal transmission, risk factors and outcomes of a COVID19+ pregnancy, and how the virus can be passed from mother to baby in the population of Mayo Clinic patients.